Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 4(2)

Phase 1(1)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07220538Phase 4Recruiting

A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment

Role: lead

NCT04525144Phase 2Recruiting

EGb 761 in the Syndrome of MCI With Concomitant CVD

Role: collaborator

NCT02174653Phase 3Completed

Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides)

Role: lead

NCT01411709Phase 4Completed

A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress

Role: collaborator

NCT00982501Phase 1Completed

WS®1442 in Slightly Overweight Subjects

Role: lead

All 5 trials loaded